The biopharmaceutical company said that its subsidiary, Biocon Biologics has secured market entry for its proposed biosimilar, Bmab 1200, which is designed to compete with Stelara, in Europe, the UK, Canada, and Japan.
| Subscribe To Our Free Newsletter |
